|
|
| | Tosufloxacin p-Toluenesulfonate Hydrate Basic information |
| Product Name: | Tosufloxacin p-Toluenesulfonate Hydrate | | Synonyms: | Tosufloxacin (tosylate hydrate);Tosufloxacin p-Toluenesulfonate Hydrate;1,8-Naphthyridine-3-carboxylic acid, 7-(3-amino-1-pyrrolidinyl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-, 4-methylbenzenesulfonate, hydrate (1:1:);A-61827 tosylate hydrate;T-3262 Tosylate Hydrate;Tosufloxacin tosylate hydrate (T3262, A61827);Tosufloxacin tosylate hydrate, 10 mM in DMSO;Tosufloxacin toluenesulfonate hydrate - Bio-X ? | | CAS: | 1400591-39-0 | | MF: | C26H23F3N4O6S | | MW: | 576.55 | | EINECS: | | | Product Categories: | | | Mol File: | 1400591-39-0.mol |  |
| | Tosufloxacin p-Toluenesulfonate Hydrate Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO : ≥ 33 mg/mL (55.50 mM) | | form | Solid | | color | White to off-white |
| | Tosufloxacin p-Toluenesulfonate Hydrate Usage And Synthesis |
| Uses | Tosufloxacin tosylate hydrate (A-61827) is an orally active fluoroquinolone antibiotic. Tosufloxacin shows a broad spectrum of antibacterial activity against gram-positive and gram-negative bacteria[1][2]. | | Definition | ChEBI: A racemate comprising equimolar amounts of (R)- and (S)-tosufloxacin tosylate hydrate. | | in vivo | Tosufloxacin tosylate hydrate (T-3262) (oral gavage; 0.16-13.39 mg/kg; once) treatment shows antibacterial activity against S. aureus, E. coli, and P. aeruginosa in vivo[2]. | Animal Model: | Male Slc:ICR mice infected with S. aureus[2] | | Dosage: | 1.27-2.15 mg/kg | | Administration: | Oral gavage; 1.27-2.15 mg/kg; once | | Result: | Showed 50% effective dose (ED50) of 1.62 mg/kg (body weight) at 7 days after infection.
Showed MIC value of 0.0125 μg/mL. |
| Animal Model: | Male Slc:ICR mice infected with E. coli[2] | | Dosage: | 0.16-0.30 mg/kg | | Administration: | Oral gavage; 0.16-0.30 mg/kg; once | | Result: | Showed 50% effective dose (ED50) of 0.22 mg/kg (body weight) at 7 days after infection.
Showed MIC value of 0.0125 μg/mL. |
| Animal Model: | Male Slc:ICR mice infected with P. aeruginosa[2] | | Dosage: | 7.66-13.39 mg/kg | | Administration: | Oral gavage; 7.66-13.39 mg/kg; once | | Result: | Showed 50% effective dose (ED50) of 10.13 mg/kg (body weight) at 7 days after infection.
Showed MIC value of 0.78 μg/mL. |
| | IC 50 | Quinolone | | References | [1] Chu DT, et al. Synthesis and biological properties of A-71497: a prodrug of tosufloxacin. Drugs Exp Clin Res. 1990;16(9):435-43. PMID:2100244
[2] Fujimaki K, et al. In vitro and in vivo antibacterial activities of T-3262, a new fluoroquinolone. Antimicrob Agents Chemother. 1988 Jun;32(6):827-33. DOI:10.1128/AAC.32.6.827 |
| | Tosufloxacin p-Toluenesulfonate Hydrate Preparation Products And Raw materials |
|